In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction

Protalix BioTherapeutics Inc.

www.protalix.com

Latest From Protalix BioTherapeutics Inc.

Bookmark
  • Analysis

Finance Watch: Five More Biopharmas Enter US Queue Even As IPO Returns Dip

By Mandy Jackson

Public Company Edition: SpringWorks has the biggest IPO ambitions of recent US filers. Also, Deciphera raises $400m after good data and Protalix seeks strategic alternatives.

Financing Strategy
Bookmark
  • News

Protalix and Chiesi Plan Q1 2020 Filing For Accelerated FDA Approval

By Scrip Team

The companies plan to use surrogate endpoint data to win approval to challenge Sanofi and Shire for the Fabry disease market.

Approvals Rare Diseases
Bookmark
  • News

Deal Watch: LEO Pharma Expands Market Reach Through Bayer Dermatology Deal

By Scrip Team

LEO Pharma is buying branded topical treatments worth more than €280m in annual sales from Bayer. Also, Apricus and Sellos agree to merge, Lilly partners on translation inhibitors with Anima, and Merck leverages Sutro's technology in cancer and autoimmune partnership.

Deals M & A
Bookmark
  • News

More Evidence Needed For Chiesi’s Ultra Orphan Lamzede, Says NICE

By Francesca Bruce

Chiesi still has work to do to convince NICE that its ultra rare disease treatment Lamzede is a cost-effective treatment.

Rare Diseases Health Technology Assessment
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
    • Transgenics
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Protalix BioTherapeutics Ltd.
  • Metabogal Ltd.
  • Orthodontix Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Protalix BioTherapeutics Inc.
  • Senior Management
  • Dror Bashan, Pres. & CEO
    Eyal Rubin, SVP, CFO
    Yoseph Shaaltiel, PhD, EVP, R&D
    Ronen Rosenberg, VP, Commercial & Product Planning
    William Taylor, VP, Bus. Dev.
  • Contact Info
  • Protalix BioTherapeutics Inc.
    Phone: (972) 4-902-8100
    2 Snunit St., Science Park
    P.O. Box 455 Karmiel, 21000
    Israel
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By